Showing results (81-90 of 161) with videos related to

Sort By:
Pageof 17
Cancer Treatment Reviews|March 24, 2020
The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptorRafael Morales-Barrera, Cristina Suárez, Macarena González, et al.
Biomed Research International|December 28, 2013
Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissuesTamara Sequeiros, Marta García, Melania Montes, et al.
Anti-Cancer Drugs|August 13, 2005
Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancerJuan Morote, Salvador Esquena, Anna Orsola, et al.
Minerva Urology and Nephrology|April 23, 2021
Surgeon preimplantation macroscopic graft appraisal improves risk stratification of deceased kidney donors: a prospective studyEnric Miret Alomar, Francesc Moreso, Nestor Toapanta, et al.
Cancer Treatment Reviews|October 16, 2016
Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New HopeRafael Morales-Barrera, Cristina Suárez, Ana Martínez de Castro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2008
PTOV1 expression predicts prostate cancer in men with isolated high-grade prostatic intraepithelial neoplasia in needle biopsyJuan Morote, Sara Fernández, Lide Alaña, et al.
Oncotarget|September 24, 2017
Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cellsVerónica Cánovas, Yolanda Puñal, Valentina Maggio, et al.
European Urology|June 24, 2014
Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancerLaurent Boccon-Gibod, Peter Albers, Juan Morote, et al.
Virchows Archiv : an International Journal of Pathology|December 25, 2010
PTOV1 is overexpressed in human high-grade malignant tumorsSara Fernández, Jose L Mosquera, Lide Alaña, et al.
Critical Reviews in Oncology/Hematology|September 14, 2015
Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancerPablo Maroto, Eduardo Solsona, Enrique Gallardo, et al.
Pageof 17